Chosen Medicine and Illumina Forge Strategic Partnership to Advance NGS-Based IVD Products for Oncology in China

Genecast Bio has entered into a strategic partnership with Illumina, Inc. (USA). The two parties will engage in in-depth collaboration to promote clinical oncology NGS in vitro diagnostic products in China, making leapfrog progress toward the industrialization of precision oncology medicine. Through this strategic partnership with Illumina, Genecast Bio will develop, apply, and promote oncology testing products based on NGS platforms.

QiuZhen Medicine is actively expanding its presence in the industrialization of oncology testing, dedicating itself to the development of standardized in vitro diagnostic products for clinical oncology. Adhering to a strategy that combines independent R&D with strategic introductions, QiuZhen Medicine has introduced Illumina’s TruSight™ Oncology 500 (TSO 500) multi-gene testing kit, aiming to provide precision medical services to a broader population of cancer patients.

Qiuzhen Medical Technology (Beijing) Co., Ltd. is a National High-Tech Enterprise and a member unit of the National Health and Medical Big Data Center. Leveraging bioinformatics and high-throughput sequencing technologies, the company has established a comprehensive presence in the field of tumor liquid biopsy, providing full-spectrum solutions for precision medicine and immunotherapy to cancer patients. Its product portfolio covers early cancer screening, companion diagnostics for targeted therapies, immune profiling, dynamic monitoring, prognostic assessment, and big data analysis of tumor bioinformatics. Qiuzhen Medical is committed to becoming a globally leading provider of end-to-end products and services in oncology precision medicine.

Illumina continues to drive advancements in life sciences, translational and consumer genomics, and molecular diagnostics through its next-generation sequencing and microarray technologies and platforms. Built on continuous innovation in sequencing technology, Illumina has become a global industry leader in DNA sequencing and biochip technology, serving research, clinical, and applied markets with products spanning life sciences, oncology, reproductive health, agriculture, and other emerging fields.